U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · First and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50; Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory tract disease caused by RSV
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · ABRYSVO is a bivalent vaccine that was designed to provide protection against RSV-LRTD, regardless of the virus subgroup. In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine.
The new RSV vaccines for older adults - Mayo Clinic Press
Sep 19, 2023 · Both vaccines are currently available. Here’s what you need to know about RSV and the two new vaccines designed to protect against it. What is RSV? Respiratory syncytial virus, commonly referred to as just “RSV,” is an RNA virus that can cause cold-like symptoms and lung and respiratory tract infections. RSV has an A subtype and a B subtype.
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name...
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to ... - MedCity News
May 31, 2024 · Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · mRESVIA ® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells.
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F...
Moderna Receives Health Canada Approval for RSV Vaccine for …
6 days ago · CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 1.
Canada approves Moderna's RSV vaccine for those age 60 and …
5 days ago · Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for ...
FDA approves mRNA-based RSV vaccine - Nature
Jun 7, 2024 · The FDA has approved Moderna’s mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) to protect adults aged 60 years and older from lower respiratory tract disease....